Dexaject Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

WARNINGS:  Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.

Additionally, corticosteroids administered to dogs, rabbits, and rodents during pregnancy have produced cleft palate.  Other congenital anomalies including deformed forelegs, phocomelia, and anasarca have been reported in offspring of dogs which received corticosteroids during pregnancy.

A withdrawal period has not been established for this product in pre-ruminating calves.  Do not use in calves to be processed for veal.

SIDE EFFECTS:  Side effects, such as SAP and SGPT enzyme elevations, weight loss, anorexia, polydipsia, and polyuria, have occurred following the use of synthetic corticosteroids in dogs.  Vomiting and diarrhea (occasionally bloody) have been observed in cats and dogs.  Cushing's syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.

Corticosteroids reportedly cause laminitis in horses.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.


INDICATIONS:  DEXAJECT is indicated for the treatment of primary bovine ketosis and as an anti-inflammatory agent in the bovine and equine.

As supportive therapy, DEXAJECT may be used in the management of various rheumatic, allergic, dermatologic, and other diseases known to be responsive to anti-inflammatory corticosteroids.  DEXAJECT may be used intravenously as supportive therapy when an immediate hormonal response is required.

Bovine Ketosis:  DEXAJECT is offered for the treatment of primary ketosis.  The gluconeogenic effects of DEXAJECT, when administered intramuscularly, are generally noted within the first 6 to 12 hours.  When DEXAJECT is used intravenously, the effects may be noted sooner.  Blood sugar levels rise to normal levels rapidly and generally rise to above normal levels within 12 to 24 hours.  Acetone bodies are reduced to normal concentrations usually within 24 hours.  The physical attitude of animals treated with DEXAJECT brightens and appetite improves, usually within 12 hours.  Milk production, which is suppressed as a compensatory reaction in this condition, begins to increase.  In some instances, it may even surpass previous peaks.  The recovery process usually takes from 3 to 7 days.

Supportive Therapy:  DEXAJECT may be used as supportive therapy in mastitis, metritis, traumatic gastritis, and pyelonephritis, while appropriate primary therapy is administered.  in these cases, the corticosteroid combats accompanying stress and enhances the feeling of general well-being.  DEXAJECT may also be used as supportive therapy in inflammatory conditions such as arthritic conditions, snake bite, acute mastitis, shipping fever, pneumonia, laminitis, and retained placenta.

Equine:  DEXAJECT is indicated for the treatment of acute musculoskeletal inflammations, such as bursitis, carpitis, osselets, tendonitis, myositis, and sprains.  If boney changes exist in any of these conditions, joints, or accessory structures, a response to DEXAJECT cannot be expected.  In addition, DEXAJECT may be used as supportive therapy in fatigue, heat exhaustion, influenza, laminitis, and retained placenta provided that the primary cause in determined and corrected.


There is currently no drug history available for this drug.

Other Information

DESCRIPTION:  Dexamethasone Solution is a synthetic analogue of prednisolone, having similar but more potent anti-inflammatory therapeutic action and diversified hormonal and metabolic effects.  Modification of the basic corticoid structure as acheived in DEXAJECT offers enhanced anti-inflammatory effect compared to older corticosteroids.  The dosage of DEXAJECT required is markedly lower than that of prednisone and prednisolone.

DEXAJECT is not species-specific; however, the veterinarian should read the sections on INDICATIONS, DOSAGE, SIDE EFFECTS, CONTRAINDICATIONS, PRECAUTIONS, and WARNINGS before this drug is used.

DEXAJECT  is intended for intravenous or intramuscular administration.  Each mL contains 2 mg dexamethasone, 500 mg polyethylene glycol 400, 9 mg benzyl alcohol, 1.8 mg methylparaben and 0.2 mg propylparaben as preservatives, 4.75 percent alcohol, HCl to adjust pH to approximately 4.9, water for injection q.s.

Dexaject Manufacturers

  • Butler Schein Animal Health
    Dexaject (Dexamethasone) Injection, Powder, For Solution [Butler Schein Animal Health]

Login To Your Free Account